Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Donafenib, Sintilimab, and HAIC for Neoadjuvant Resectable HCC
NCT06512467Phase 2Not yet recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Jul 2024
- Primary completion
- Jul 2026
- Modality
- Small Molecules, Monoclonal Antibodies
01
Overview
A Phase 2 trial of donafenib, sintilimab in hepatocellular carcinoma (HCC), sponsored by Tianjin Medical University Cancer Institute and Hospital. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
donafenibsintilimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06512467.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06512467.